Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2011-02-25 Investor Presentation
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Unternehmenspräsentation, Februar 2011
Investor Presentation Classification · 98% confidence The document text is titled "Unternehmenspräsentation" (Company Presentation) and contains slides/sections typical of an investor presentation, such as 'Strategie & Geschäftsmodell', 'Finanzstrategie & Ausblick', and detailed process descriptions ('Lösungen im Wirkstoffforschungsprozess'). It explicitly mentions financial results for 2010 and growth expectations for 2011, along with forward-looking statements referencing the Form 20-F filing. The structure, content (strategy, pipeline, financials), and the explicit mention of it being a 'Unternehmenspräsentation' strongly indicate this is an Investor Presentation (IP). The document length is substantial (78k characters), ruling out a simple Report Publication Announcement (RPA).
2011-02-25 German
Declaration of Compliance 2010
Governance Information Classification · 98% confidence The document is explicitly titled "Declaration on the German Corporate Governance Code for the Year 2010". It details compliance, exceptions, and adherence to specific sections of the German Corporate Governance Code (§ 161 AktG). This content directly relates to the company's internal rules, board structure, and governance practices, matching the definition for Governance Information (CGR). The document length is short (2199 chars), but its content is a formal declaration/report itself, not just an announcement of a report's publication, thus CGR is more specific than RPA or RNS.
2011-02-20 English
Entsprechenserklärung 2010
Governance Information Classification · 99% confidence The document is titled "Entsprechenserklärung zum Deutschen Corporate Governance Kodex für das Jahr 2010" (Declaration of Conformity with the German Corporate Governance Code for the year 2010). This explicitly states that the document details the company's adherence (or deviations) from corporate governance rules. This aligns directly with the definition of Governance Information (CGR), which covers internal rules, board structure, and governance practices.
2011-02-20 German
Earnings Release 2011
Earnings Release Classification · 99% confidence The document is a research publication from DZ BANK AG concerning the company Evotec. It contains detailed financial forecasts (2010e through 2014e), key performance indicators, valuation metrics, and an analysis of a recent acquisition (Kinaxo). The structure, including tables with historical data, future estimates ('e' for estimate), and a clear recommendation ('Kaufempfehlung' - Buy Recommendation), strongly indicates this is an analyst research report providing forward-looking financial analysis and valuation updates. This fits the description of an Investor Presentation (IP) or a detailed analysis document, but given the context of a bank publishing research with explicit financial models and target prices, it is best classified as an Investor Presentation (IP) which often includes detailed financial models and investment rationale, or potentially a specialized form of Financial Supplement Data (XLSX) if it were purely data, but the narrative and recommendation push it towards IP. However, looking closely at the definitions, 'Investor Presentation (IP)' is for detailed presentations focusing on financials, strategy, and market position. This document serves exactly that purpose from an analyst's perspective. It is not a formal company filing (like 10-K or ER). Since it is a detailed analysis/forecast document, IP is the most appropriate fit among the provided options, as it contains more than just highlights (ER) or just raw data (XLSX). FY 2011
2011-02-20 German
M&A Activity 2011
M&A Activity Classification · 99% confidence The document contains a detailed financial analysis dated February 11, 2011, including a recommendation (BUY), price target, key financial tables (Y/E 2008-2012E), share data, performance metrics, and a short company profile. It explicitly mentions a major corporate action: the acquisition of Kinaxo Biotechnologies GmbH. This structure—a detailed report with forecasts, performance data, and an analyst recommendation—is characteristic of an Investor Presentation (IP) or a detailed research report, rather than a mandatory regulatory filing like a 10-K or a brief Earnings Release (ER). Since it is a comprehensive presentation of analysis, strategy, and financials aimed at investors, 'Investor Presentation' (IP) is the most fitting category, although it strongly resembles a sell-side research report. Given the provided options, IP covers detailed analysis and strategy presentation best.
2011-02-12 English
Earnings Release 2011
Earnings Release Classification · 99% confidence The document is titled 'EQUITY RESEARCH +++URGENT+++ COMPANY ALERT' and contains an analyst's rating ('BUY'), target price changes, financial forecasts, and extensive regulatory disclosures typical of investment bank research reports. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or an interim report (IR). It is a detailed analysis provided by a third party (LBBW) to investors, which aligns best with the 'Investor Presentation' (IP) category, as it presents investment rationale, forecasts, and performance data, although it is technically a research note. However, given the specific definitions, this document is a detailed analysis/presentation of investment opinion and financial projections, making 'Investor Presentation' (IP) the most fitting category among the choices, as it functions as a detailed investment pitch/update, even if not a formal slide deck. FY 2011
2011-02-10 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.